← Back to Clinical Trials
Recruiting NCT06898762

NCT06898762 Creation of a National Multicenter Platform for the Study of Inflammatory Myocardial Disease: Pre-MYO Cohort

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06898762
Status Recruiting
Phase
Sponsor Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Condition Myocarditis Acute
Study Type OBSERVATIONAL
Enrollment 3,000 participants
Start Date 2023-04-09
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age N/A
Study Type OBSERVATIONAL
Interventions
characterization of a large national cohort of patients with suspected myocarditis or inflammatory cardiomyopathy.

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 3,000 participants in total. It began in 2023-04-09 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The objectives of this project are: 1) to comprehensively characterize a large national cohort of patients with suspected myocarditis, their clinical phenotype, care management, blood and imaging biomarkers, epidemiological, environmental and genetic data; 2) to retrospectively validate the accuracy of the new hsa-RNA-Chr8:96 biomarker for the diagnosis of myocarditis compared to conventional diagnosis; 3) to identify acquired and inherited mutations, and their interaction with the environment, which explain the susceptibility to myocarditis, its severity and response to treatment; 4) to study the lower incidence in women and the influence of age, considering socio-health and genetic factors.

Eligibility Criteria

Inclusion Criteria: • Presence of at least one compatible symptom and at least one objective finding in diagnostic tests (Figure 2), according to the consensus document of the European Society of Cardiology (1): A. Clinical presentation: * Acute chest pain: pericardial or pseudo-ischemic. * Dyspnea on exertion or at rest for up to 3 months. * Dyspnea on exertion or at rest for 3 months - 1 year. * Unexplained palpitations / arrhythmias, sudden death recovered. * Unexplained cardiogenic shock. B. Findings in complementary tests: * ECG: new onset AV block, new onset bundle branch block, ST segment elevation/depression, T wave inversion * Elevation of TnI/TnT * Segmental or global contractility alterations not explained by other causes * Positive Lake Louise criteria in cardiac MRI (13) (Annex III Figure S1) • Patients who have given their informed consent.

Contact & Investigator

Central Contact

Domingo Pascual Figal, MD

✉ coordinacion@premyo.org

📞 868885273

Principal Investigator

Domingo Pascual Figal, MD

PRINCIPAL INVESTIGATOR

HCUVA

Frequently Asked Questions

Who can join the NCT06898762 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, studying Myocarditis Acute. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06898762 currently recruiting?

Yes, NCT06898762 is actively recruiting participants. Contact the research team at coordinacion@premyo.org for enrollment information.

Where is the NCT06898762 trial being conducted?

This trial is being conducted at Murcia, Spain.

Who is sponsoring the NCT06898762 clinical trial?

NCT06898762 is sponsored by Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia. The principal investigator is Domingo Pascual Figal, MD at HCUVA. The trial plans to enroll 3,000 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology